MY160074A - Protopanaxadiol-type ginsenoside compositions and uses thereof - Google Patents

Protopanaxadiol-type ginsenoside compositions and uses thereof

Info

Publication number
MY160074A
MY160074A MYPI2010003500A MYPI2010003500A MY160074A MY 160074 A MY160074 A MY 160074A MY PI2010003500 A MYPI2010003500 A MY PI2010003500A MY PI2010003500 A MYPI2010003500 A MY PI2010003500A MY 160074 A MY160074 A MY 160074A
Authority
MY
Malaysia
Prior art keywords
protopanaxadiol
compositions
ginsenoside compositions
ginsenoside
type ginsenoside
Prior art date
Application number
MYPI2010003500A
Other languages
English (en)
Inventor
E Daley Thomas
Tempesta Michael
Original Assignee
Raptor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raptor Therapeutics Inc filed Critical Raptor Therapeutics Inc
Publication of MY160074A publication Critical patent/MY160074A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
MYPI2010003500A 2008-01-24 2009-01-23 Protopanaxadiol-type ginsenoside compositions and uses thereof MY160074A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2331008P 2008-01-24 2008-01-24

Publications (1)

Publication Number Publication Date
MY160074A true MY160074A (en) 2017-02-15

Family

ID=40578016

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2010003500A MY160074A (en) 2008-01-24 2009-01-23 Protopanaxadiol-type ginsenoside compositions and uses thereof

Country Status (13)

Country Link
US (1) US8440632B2 (enExample)
EP (1) EP2254569B1 (enExample)
JP (1) JP5523348B2 (enExample)
KR (2) KR20160048228A (enExample)
CN (1) CN101977600B (enExample)
AU (1) AU2009206753B2 (enExample)
CA (1) CA2713104C (enExample)
DK (1) DK2254569T3 (enExample)
ES (1) ES2400491T3 (enExample)
MY (1) MY160074A (enExample)
NZ (1) NZ587134A (enExample)
TW (1) TWI440463B (enExample)
WO (1) WO2009094177A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5563285B2 (ja) * 2009-12-14 2014-07-30 ライオン株式会社 飲食品、医薬品、又は医薬部外品、並びに、プロトパナキサトリオールの安定化方法、及びプロトパナキサジオールの安定化方法
WO2013078371A2 (en) 2011-11-22 2013-05-30 The Johns Hopkins University Methods and compositions for reducing alcohol toxicity
KR101446743B1 (ko) * 2012-06-11 2014-10-01 한국생명공학연구원 실리마린을 유효성분으로 포함하는 알콜성 위궤양 예방 및 치료용 조성물
CN102727508B (zh) * 2012-07-15 2014-09-24 浙江大学 人参二醇皂苷组分制备及在防治帕金森氏病中的药物用途
US11338120B2 (en) 2012-08-29 2022-05-24 Palo Alto Investors LP Methods and devices for treating parasympathetic bias mediated conditions
WO2014178803A1 (en) * 2013-04-29 2014-11-06 Alkoçlar Erdal Can A composition for use in the treatment of alcohol addiction
KR101621356B1 (ko) * 2014-09-05 2016-05-17 한국과학기술원 진세노사이드 f2의 간 질환 예방 또는 치료 용도
KR102299294B1 (ko) * 2014-10-28 2021-09-07 로버스트 씨드 테크놀로지 에이 앤드 에프 악티에볼라그 종자 프라이밍을 위한 개선된 방법
ES2926494T3 (es) * 2015-03-26 2022-10-26 Sen Jam Pharmaceutical Llc Combinación de naproxeno y fexofenadina para inhibir los síntomas asociados con veisalgia
KR101641477B1 (ko) * 2016-01-19 2016-07-20 이국진 홍삼 추출물을 이용한 커피나무의 재배방법
CN106619669B (zh) * 2016-12-02 2019-03-29 延边大学 原人参二醇皂苷在制备防治炎症疾病的药物中的应用
CN106511360A (zh) * 2016-12-02 2017-03-22 上海芮范生物科技有限公司 一种含有人参皂苷Rg3和水飞蓟素的组合物及药物
CN107441104B (zh) * 2017-08-24 2023-07-21 浙江大学 人参二醇皂苷Rb组分防治糖尿病并发症及代谢紊乱相关疾病的医药用途
KR102053208B1 (ko) * 2018-03-15 2019-12-06 숙명여자대학교 산학협력단 진세노사이드 Rb1 및 Rb2를 유효성분으로 함유하는 근육 재생용 조성물
KR102138252B1 (ko) * 2018-05-16 2020-07-29 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 효모의 nadph 관련 생합성 경로의 개량을 통한 진세노사이드 생산 증대
CN111053782B (zh) * 2018-10-17 2024-07-05 株式会社爱茉莉太平洋 包含人参皂苷的组合物
US11000538B2 (en) * 2018-10-31 2021-05-11 Amorepacific Corporation Composition for enhancing exercise ability or anti-fatigue comprising novel ginsenoside
KR102672902B1 (ko) * 2018-10-31 2024-06-10 (주)아모레퍼시픽 신규 진세노사이드를 포함하는 숙취 해소용 조성물
CN109758464B (zh) * 2019-03-21 2019-10-25 淮阴师范学院 越南人参皂苷r4在制备神经退行性疾病治疗药物中的应用
KR20220081351A (ko) 2019-10-10 2022-06-15 조브리어스 파르마 에이에스 개선된 숙취해소 조성물, 이의 제조 및 용도
KR102654669B1 (ko) * 2021-06-30 2024-04-04 경희대학교 산학협력단 실리디아닌을 포함하는 인삼 금 나노에멀젼 및 이의 용도

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1574806A (en) 1976-06-03 1980-09-10 Inverni Della Beffa Spa Production of purified ginseng extracts and pharmaceutical compositions containing the extracts
US4966893A (en) 1989-01-13 1990-10-30 Pang Peter K T Method for treatment of senile dementia
JPH04316448A (ja) 1991-04-12 1992-11-06 Iwatani Internatl Corp 人参微粉末の製造方法
US5547671A (en) * 1995-09-20 1996-08-20 Duthinh; Phu Anti-intoxication composition
JP3656972B2 (ja) * 1997-02-14 2005-06-08 丸善製薬株式会社 アルコール臭低減剤
US6083932A (en) 1997-04-18 2000-07-04 Cv Technologies Inc. Pharmaceutical compositions derived from ginseng and methods of treatment using same
KR20010023208A (ko) 1997-08-28 2001-03-26 브루스, 제임스 에이취 허브 추출물의 화학 및 약리학적 표준화
KR20020035855A (ko) 1999-08-30 2002-05-15 마쯔오 미쯔요시 약용인삼을 포함하는 뇌세포 또는 신경세포 보호제
CA2307393A1 (en) * 2000-05-01 2001-11-01 The University Of British Columbia Ginsenoside chemotherapy
CN1167424C (zh) * 2000-11-18 2004-09-22 唐修文 三七人参皂甙肠溶片
US7011096B2 (en) * 2001-08-31 2006-03-14 Philip Morris Usa Inc. Oxidant/catalyst nanoparticles to reduce carbon monoxide in the mainstream smoke of a cigarette
US20030185910A1 (en) * 2002-02-08 2003-10-02 Taik Koo Yun Cancer preventive composition comprising ginsenoside glycosides of red ginseng
US6936283B2 (en) * 2003-07-25 2005-08-30 Langeland Bjoern T. Composition for stimulation of specific metallo-enzymes
US7186517B2 (en) * 2003-08-01 2007-03-06 Aesgen, Inc. Compositions and methods for monitoring breast cancer treatment
CN100563668C (zh) * 2003-08-18 2009-12-02 株式会社柳柳 使用醋的人参制剂及其加工
KR20050081247A (ko) * 2004-02-12 2005-08-18 이처준 홍삼 및 흑삼을 이용한 해장국 제조 방법.
US20080021083A1 (en) * 2004-03-03 2008-01-24 Daley Thomas E 4-Methylpyrazole Formulations for Inhibiting Ethanol Intolerance
KR100547253B1 (ko) 2004-05-29 2006-01-26 박명환 암 예방 및 치료에 유효한 진세노사이드 유도체
CN1698879B (zh) * 2005-06-21 2010-08-11 蔺益民 具有解酒护肝功能的产品及制备方法和用途
PL1909600T3 (pl) * 2005-07-29 2012-09-28 Tima Found Kompozycja spowalniająca metabolizm alkoholu i ograniczająca ryzyko chorób wywołanych alkoholem

Also Published As

Publication number Publication date
AU2009206753A1 (en) 2009-07-30
AU2009206753B2 (en) 2014-07-03
CN101977600B (zh) 2013-02-27
KR101648987B1 (ko) 2016-08-17
US8440632B2 (en) 2013-05-14
CA2713104A1 (en) 2009-07-30
TW200936144A (en) 2009-09-01
ES2400491T3 (es) 2013-04-10
HK1144772A1 (en) 2011-03-11
WO2009094177A1 (en) 2009-07-30
DK2254569T3 (da) 2013-02-25
TWI440463B (zh) 2014-06-11
KR20160048228A (ko) 2016-05-03
CN101977600A (zh) 2011-02-16
KR20100111300A (ko) 2010-10-14
JP5523348B2 (ja) 2014-06-18
JP2011510075A (ja) 2011-03-31
EP2254569B1 (en) 2012-11-28
US20110065659A1 (en) 2011-03-17
CA2713104C (en) 2016-07-12
EP2254569A1 (en) 2010-12-01
NZ587134A (en) 2012-04-27

Similar Documents

Publication Publication Date Title
MY160074A (en) Protopanaxadiol-type ginsenoside compositions and uses thereof
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
AU2007257423A8 (en) Purine analogs
WO2012116290A3 (en) Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
NZ734050A (en) Compositions comprising povidone-iodine
BR112012018386A8 (pt) "inibidores isoindolinona de fosfatidilinositol 3-quinase"
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
MX2010004614A (es) Composiciones para tratamiento del mal de parkinson.
MX2010009623A (es) Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
SG10201809638YA (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
EP4327867A3 (en) Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
EP2512479A4 (en) METHOD AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE
WO2005116002A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2007061661A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2009109616A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxrl and p40
UA105644C2 (uk) Способи лікування легеневих порушень складами ліпосомального амікацину
BRPI0806392A8 (pt) uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
MX352647B (es) Metodo para temporizar una colonoscopia en donde se administra una composicion de picosulfato.
WO2007002862A3 (en) Compositions and methods for treatment of cycle-related symptoms
PH12013500293A1 (en) Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
WO2011028799A3 (en) Ganglioside transmucosal formulations